PBM Formulary Exclusions In Oncology Are On The Rise
Physician-Administered Drugs Make Up Nearly Half Of Oncology Exclusions
Executive Summary
Oncology drugs are no longer immune to pharmacy benefit management formulary exclusions in the commercial market and even drugs administered in a physician’s office are increasingly being subjected to rebate-driven coverage decisions.
You may also be interested in...
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
The Booming Business Of Drug Exclusions
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December
Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.